CORVUS PHARMACEUTICALS INC. - COMMON STOCK

5,4600

10-января-25 10:43:03

15 мин. задержка

Акции

-0,1900

-3,36%

Сегодняшний диапазон

5,2600 - 5,5750

ISIN

N/A

Источник

NASDAQ

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

01 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

31 июл 2024 08:30:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

30 июл 2024 09:55:53 Источник NetDania Notify
NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

29 июл 2024 12:38:28 Источник NetDania Notify
NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

26 июл 2024 11:47:58 Источник NetDania Notify
Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases

25 июл 2024 08:30:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

30 май 2024 16:02:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

06 май 2024 16:01:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

02 май 2024 16:02:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

02 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

09 апр 2024 16:01:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

19 мар 2024 16:02:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

13 мар 2024 16:02:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

12 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

08 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

06 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

23 янв 2024 17:00:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

09 дек 2023 12:00:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

07 ноя 2023 16:01:00 Источник Nasdaq GlobeNewswire
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

02 ноя 2023 09:15:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.